Leading Cancer Centers Join GenomeDx’s Decipher GRID
SAN DIEGO, April 6, 2016 /PRNewswire/ — GenomeDx Biosciences today announced that it has entered into seven recent agreements with leading cancer centers to provide access to GenomeDx’s genomic database and data sharing program – Decipher Genomics Resource Information Database (Decipher GRIDTM). These new cancer center collaborations, each of which was entered into in the first quarter of 2016, include Dana-Farber/Brigham and Women’s Cancer Center, Johns Hopkins School of Medicine, University of California San Francisco, Northwestern University Feinberg School of Medicine, H. Lee Moffitt Cancer Center & Research Institute, University of Miami and Comprehensive Urology. These institutions join Sidney Kimmel Cancer Center at Thomas Jefferson University and Cedars-Sinai Medical Center as leading cancer centers now accessing GenomeDx’s GRID network.
Decipher GRID is a cloud-based genomic data sharing and research platform that provides a foundation for collaboration, knowledge creation and innovation in urologic cancer. It contains the genomic profiles of thousands of tumors and is growing rapidly. Every patient tumor sample added contributes additional information that may be mined to advance collaborative research efforts in the area of prostate and bladder cancer.
“Decipher GRID is a unique database in urologic cancer that can be mined to uncover new genomic research insights that may eventually be translated into meaningful prognostic and diagnostic decision making tools in the clinic,” noted Doug Dolginow, M.D., chief executive officer of GenomeDx Biosciences. “We believe we can significantly accelerate the utility of genomic information and the development of genomic tools through data sharing made possible by the collaborative efforts of major cancer centers around the world.”
Peter Carroll, M.D., MPH, chair of urology at the University of California, San Francisco, added, “Decipher GRID is an exciting initiative for physicians, researchers and patients. It enables the evaluation of large groups of our patients in ways not possible before. By accessing the genomic information available through GRID, we may better understand the potential course of disease and identify patients who may be suitable for novel treatment strategies.”
“GenomeDx allows us to take an innovative approach to our treatment and management of patients with prostate cancer,” said Kirk Wojno, M.D., chief of pathology and laboratory services and director of clinical research at Comprehensive Urology in Michigan. “The broad genomic information found in Decipher GRID will allow us the ability to enhance our own clinical research, identify patients that may benefit from specific pharma and biotech industry trials and further position us as a prostate cancer center of excellence for determining the best course of treatment for our patients.”
Decipher GRID was launched in 2015 as a research initiative to engage major cancer centers and community-based urology practices in a broad collaborative effort in urologic oncology. The genomic information contained in Decipher GRID has been used to develop GenomeDx’s commercially-available Decipher prostate cancer classifier tests. The Decipher tests utilize a whole genome platform to evaluate the activity of 22 expression-based biomarkers from RNA proven to be important in predicting the aggressiveness of prostate cancer. Decipher GRID makes use of the thousands of other genes contained within the tumor genome to identify additional biomarkers that may be predictive of treatment response.
About Decipher® Prostate Cancer Classifier Tests
Our Decipher prostate cancer classifier tests are currently comprised of Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient’s unique genomic profile. Decipher Biopsy is indicated for men after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.
Learn more at www.DecipherTest.com
About Decipher GRID™
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic data sharing platform that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patients, and constitutes what we believe to be the world’s largest shared, clinically-annotated genomic expression database in urologic oncology and one of the world’s largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables more rapid discovery, development, commercialization and adoption of existing and new products. Through Decipher GRID, GenomeDx is building a suite of genomic tests to assist physicians and patients with clinical decision-making from disease screening through late-stage therapy.
Learn more at www.DecipherGRID.com
About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic oncology that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx’s Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. GenomeDx is based in Vancouver, British Columbia and San Diego, California.
Learn more at www.GenomeDx.com
